Moleculin Biotech Past Earnings Performance
Past criteria checks 0/6
Moleculin Biotech's earnings have been declining at an average annual rate of -17.1%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-17.1%
Earnings growth rate
21.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -403.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Revenue & Expenses Breakdown
How Moleculin Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -30 | 9 | 20 |
| 30 Jun 24 | 0 | -25 | 9 | 18 |
| 31 Mar 24 | 0 | -27 | 10 | 18 |
| 31 Dec 23 | 0 | -30 | 10 | 19 |
| 30 Sep 23 | 0 | -26 | 11 | 17 |
| 30 Jun 23 | 0 | -29 | 11 | 20 |
| 31 Mar 23 | 0 | -30 | 12 | 20 |
| 31 Dec 22 | 0 | -29 | 12 | 19 |
| 30 Sep 22 | 0 | -25 | 11 | 18 |
| 30 Jun 22 | 0 | -21 | 10 | 16 |
| 31 Mar 22 | 0 | -18 | 9 | 15 |
| 31 Dec 21 | 0 | -16 | 8 | 14 |
| 30 Sep 21 | 0 | -16 | 8 | 13 |
| 30 Jun 21 | 0 | -15 | 8 | 13 |
| 31 Mar 21 | 0 | -21 | 7 | 14 |
| 31 Dec 20 | 0 | -17 | 7 | 13 |
| 30 Sep 20 | 0 | -19 | 7 | 14 |
| 30 Jun 20 | 0 | -19 | 7 | 13 |
| 31 Mar 20 | 0 | -10 | 7 | 11 |
| 31 Dec 19 | 0 | -13 | 6 | 11 |
| 30 Sep 19 | 0 | -12 | 6 | 11 |
| 30 Jun 19 | 0 | -10 | 6 | 9 |
| 31 Mar 19 | 0 | -14 | 5 | 11 |
| 31 Dec 18 | 0 | -12 | 5 | 10 |
| 30 Sep 18 | 0 | -12 | 5 | 9 |
| 30 Jun 18 | 0 | -13 | 5 | 9 |
| 31 Mar 18 | 0 | -11 | 5 | 5 |
| 31 Dec 17 | 0 | -10 | 4 | 5 |
| 30 Sep 17 | 0 | -8 | 4 | 3 |
| 30 Jun 17 | 0 | -7 | 3 | 3 |
| 31 Mar 17 | 0 | -4 | 3 | 2 |
| 31 Dec 16 | 0 | -4 | 2 | 1 |
Quality Earnings: MBRX is currently unprofitable.
Growing Profit Margin: MBRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MBRX is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare MBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MBRX has a negative Return on Equity (-403.13%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 21:12 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Moleculin Biotech, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |
| null null | Roth MKM |